HW021199 片进入 II 期临床试验研究的公告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法 律责任。 人福医药集团股份公司（以下简称"公司"或"人福医药"）子公司湖北生物医药 产业技术研究院有限公司（以下简称"研究院有限公司"，公司持有其84.19%的股权）、 武汉人福利康药业有限公司（以下简称"人福利康"，公司及全资子公司持有其70.28% 的股权，根据增资协议的远期回购约定，公司持有其100%权益）的研发项目HW021199 片于近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了IIa期临床试 验登记信息，现将相关情况公告如下： 一、IIa期临床试验相关情况 试验登记号：CTR20232439 证券代码：600079 证券简称：人福医药 编号：临 2023-086 号 人福医药集团股份公司关于 试验通俗题目：一项评价HW021199片用于特发性肺纤维化患者有效性和安全性的 IIa期临床试验。 二、HW021199片主要情况介绍 HW021199片适用于特发性肺纤维化的治疗。目前全球范围内尚无同靶 ...

证券代码：600079 证券简称：人福医药 编号：临 2023-083 号 人福医药集团股份公司 第十届董事会第五十四次会议决议公告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法 律责任。 人福医药集团股份公司（以下简称"人福医药"或"公司"）第十届董事会第五十 四次会议于2023年8月16日（星期三）上午10:00以通讯表决方式召开，会议通知已于2023 年8月9日通过邮件的方式送达各位董事。会议应到董事八名，实到董事八名。 本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公司 章程》的规定，会议由董事长李杰先生主持，会议审议并通过了以下议案： 议案一、关于为公司及子公司提供担保的议案 公司 2022 年年度股东大会审议通过了《关于 2023 年度预计为子公司提供担保的议 案》，2023 年第一次临时股东大会审议通过了《关于调整 2023 年度预计担保额度的议 案》，在上述授权范围内，公司董事会同意实施以下担保事项： 1、同意公司控股子公司湖北葛店人福药业有限责任公司（以下简称"葛店人福"）、 ...

关于为控股子公司提供关联担保的公告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法 律责任。 证券代码：600079 证券简称：人福医药 编号：临 2023-085 号 人福医药集团股份公司董事会 重要内容提示 ● 被担保人名称： ● 在授权范围内，人福医药集团股份公司（以下简称"人福医药"或"公司"）本次实 施的担保金额及已实际为其提供的担保余额（包含尚未使用的额度）： | 担保 | 被担 | 被担保方 最近一期 | | 期 | | 担保金额 | 已实际为 其提供的 | 股东大会授 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 授信银行 | | 备注 | | | 权担保额度 | | 方 | 保方 | 资产负债 | | 限 | | (万元) | 担保余额 | (万元) | | | | 率 | 中国光大银行股 | | | | （万元） | | | 人福 | 葛店 | | 份有限公司武汉 分行 中国银行股份有 | 1 年 1 年 | 新增 ...

证券代码：600079 证券简称：人福医药 编号：临 2023-084 号 人福医药集团股份公司董事会 关于为公司及子公司提供担保的公告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 6、北京巴瑞医疗器械有限公司（以下简称"北京医疗"）； 7、湖北人福诺生药业有限责任公司（以下简称"人福诺生"）； 8、人福医药天门有限公司（以下简称"人福天门"）。 重要内容提示 ●被担保人名称： 1、人福医药集团股份公司（以下简称"人福医药"或"公司"）； 2、宜昌人福药业有限责任公司（以下简称"宜昌人福"）； 3、人福普克药业（武汉）有限公司（以下简称"武汉普克"）； 4、武汉人福药业有限责任公司（以下简称"武汉人福"）； 5、新疆维吾尔药业有限责任公司（以下简称"新疆维药"）； ●在授权范围内，本次实施的担保金额及已实际为其提供的担保余额（包含尚未使用的额 度）： | 担保 | 被担 | 被担保方最 | | | | 担保金额 | 已实际为其 | 股东大会授 | | --- | --- | --- | --- | --- ...

Corporate Governance and Compliance - The board of directors proposed a cash dividend of 1.60 RMB per 10 shares (including tax) to all shareholders, pending approval at the 2022 annual general meeting[4]. - The company reported a standard unqualified audit opinion from Da Xin Certified Public Accountants[3]. - The company confirmed the existence of non-operating fund occupation by controlling shareholders and other related parties[5]. - The company has not violated decision-making procedures for external guarantees[5]. - The company emphasizes timely and accurate information disclosure, adhering to relevant regulations to protect investor rights[147]. - The company has a governance structure in place with a supervisory board consisting of 5 members, including 2 employee representatives, ensuring compliance with legal requirements[146]. - The company has actively engaged in investor relations management, providing multiple communication channels to address investor inquiries[148]. - The company has conducted internal training on regulatory changes to enhance compliance awareness among its board and management[150]. - The company has not experienced any insider trading incidents related to sensitive information disclosure during the reporting period[148]. - The company has strengthened its internal control systems, revising the internal control manual and financial management systems to prevent fund occupation[150]. - The company has not faced any penalties from securities regulatory agencies in the past three years, indicating compliance with regulations[161]. - The company confirmed that there were no dissenting opinions from the board regarding the financial reports and operational plans presented[172]. - The company is focused on maintaining the integrity of its financial reporting and ensuring the independence of its auditors[168]. - The board has not identified any risks during the reporting period, indicating a stable operational environment[172]. Financial Performance - The company's operating revenue for 2022 was approximately ¥22.34 billion, representing an increase of 8.71% compared to ¥20.55 billion in 2021[17]. - Net profit attributable to shareholders reached approximately ¥2.48 billion, an increase of 88.60% from ¥1.32 billion in the previous year[17]. - The net profit after deducting non-recurring gains and losses was approximately ¥1.55 billion, up 53.92% from ¥1.01 billion in 2021[17]. - The company's cash flow from operating activities was approximately ¥2.44 billion, reflecting a 12.04% increase from ¥2.18 billion in 2021[17]. - The total assets at the end of 2022 were approximately ¥36.02 billion, a slight increase of 1.74% from ¥35.41 billion at the end of 2021[17]. - The net assets attributable to shareholders increased to approximately ¥15.04 billion, marking a growth of 16.13% from ¥12.95 billion in 2021[17]. - Basic earnings per share for 2022 were ¥1.54, an increase of 85.54% compared to ¥0.83 in 2021[18]. - The weighted average return on equity rose to 17.63%, an increase of 6.73 percentage points from 10.90% in 2021[18]. - The company reported a net profit of approximately ¥259 million in Q4 2022, down from ¥721 million in Q3 2022[19]. - Non-recurring gains and losses totaled approximately ¥936 million in 2022, significantly higher than ¥311 million in 2021[20]. - The company achieved operating revenue of 22.338 billion yuan, an increase of 8.71% compared to the same period last year[26]. - The net profit attributable to shareholders reached 2.484 billion yuan, a significant increase of 88.60% year-on-year[26]. - The net profit excluding non-recurring gains and losses was 1.548 billion yuan, up 53.92% from the previous year[26]. - The company reduced interest-bearing liabilities by approximately 2.7 billion yuan, resulting in a decrease of interest expenses by 126 million yuan year-on-year[26]. - The asset-liability ratio improved from 55.79% at the beginning of the period to 50.19% at the end of the period[29]. - The company sold various equity stakes and recovered investment funds of approximately 3.9 billion yuan, achieving an investment income of about 800 million yuan[29]. - The company reported a foreign exchange gain of approximately 182 million yuan due to currency fluctuations[26]. Research and Development - The company is focusing on the development of innovative drugs and specialty generic drugs, enhancing its product competitiveness through increased R&D investment[37]. - The company has established R&D centers in Wuhan, Yichang, New Jersey, and St. Louis, employing 1,758 pharmaceutical R&D personnel, including 196 PhDs and 7 experts receiving special government allowances[91]. - The company’s R&D expenditure for 2022 was CNY 113,397.67 million, an increase of 6.92% year-on-year, representing 5.08% of the current operating revenue[100]. - The R&D investment capitalized ratio for the company was 14.74% in the reporting period, compared to an industry average of 4.19% for comparable companies[100]. - The company is actively pursuing clinical trials for drugs targeting specific conditions, such as ADHD and postoperative pain management[96]. - The company is committed to enhancing its research capabilities and ensuring compliance with regulatory standards in drug development[98]. - The company is focusing on developing seven core product lines and nurturing new growth points within established segments[129]. - The company plans to continue its cash dividend policy while also supporting funding needs for R&D, engineering projects, and business expansion[181]. Market Expansion and Strategy - The company is actively exploring international markets, with subsidiaries in Africa working on product registration despite local challenges[29]. - The company aims to expand its market presence in mature markets such as Europe and the United States, as well as emerging markets in Africa, Central Asia, and Southeast Asia[42]. - The company is committed to international expansion, leveraging existing overseas subsidiaries to enhance product and market reach[130]. - The company plans to achieve revenue of over 24 billion yuan in 2023, with a comprehensive gross margin of over 43%[131]. - The company will maintain an annual R&D investment of around 10% of pharmaceutical industrial revenue during the 14th Five-Year Plan period[129]. - The company aims to enhance market access by striving for more products, especially exclusive varieties, to enter the basic medical insurance drug catalog and actively seek qualification for centralized drug procurement and reasonable pricing[136]. - The company is pursuing market expansion through new product approvals and ongoing clinical trials for innovative therapies[94]. Environmental Responsibility - The company invested 68.662 million yuan in environmental protection during the reporting period[193]. - The total discharge of COD was 383.586 tons, with a concentration range of 80.5-287.942 mg/L, complying with the standard of 400 mg/L[193]. - The company has established environmental protection mechanisms and emphasizes compliance with national environmental laws and regulations[193]. - The company is committed to green development and continuous improvement in environmental management practices[193]. - The company has implemented effective monitoring and management of wastewater, waste gas, and hazardous waste[193]. - The company’s environmental facilities are operating normally, ensuring compliance with environmental requirements[193]. Employee Management and Compensation - The company has established a multi-faceted training program to enhance employee skills, including new employee training, professional skills training, and leadership training[176]. - The company has implemented a performance-linked floating salary mechanism as part of its compensation policy to motivate employees and ensure sustainable development[175]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 14.2746 million yuan[160]. - The company established a performance evaluation system for senior management, linking compensation and performance rewards to the achievement of business goals[187]. - The total number of employees in the parent company and major subsidiaries is 16,070, with 483 in the parent company and 15,587 in subsidiaries[173]. Risk Management - The company faces operational risks due to potential changes in tax policies affecting its subsidiaries' tax benefits, which could impact overall performance[137]. - The company is exposed to safety and environmental risks due to increased regulatory scrutiny and rising safety and environmental costs[140]. - The company is committed to strategic management and enhancing operational management levels to mitigate risks associated with its numerous subsidiaries and international operations[143].

Financial Performance - The company's operating revenue for Q1 2023 was CNY 6,225,735,090.21, representing a year-on-year increase of 20.08%[4] - The net profit attributable to shareholders decreased by 27.24% to CNY 665,316,964.81 compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 63.89% to CNY 508,455,478.82[4] - The basic earnings per share for Q1 2023 was CNY 0.41, down 28.07% year-on-year[4] - The weighted average return on net assets was 4.32%, a decrease of 2.50 percentage points compared to the previous year[4] - In Q1 2023, the company reported a net profit of ¥861,113,526.51, a decrease of 17.1% compared to ¥1,038,600,142.33 in Q1 2022[18] - The total comprehensive income for Q1 2023 was ¥862,696,980.10, down from ¥1,021,020,174.67 in Q1 2022[19] - Basic earnings per share decreased to ¥0.41 from ¥0.57 in the previous year[19] - Net profit for Q1 2023 was CNY 73,596,460.78, a significant recovery from a net loss of CNY 6,920,930.12 in Q1 2022[30] - Operating profit for Q1 2023 was CNY 73,377,418.58, compared to an operating loss of CNY 7,055,233.79 in the same period last year[30] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -518,077,556.04, indicating a cash outflow[4] - The company experienced a net cash outflow from operating activities of ¥518,077,556.04, compared to a smaller outflow of ¥35,747,537.28 in Q1 2022[22] - Net cash flow from operating activities for Q1 2023 was -347,648,507.87, an improvement from -956,933,116.45 in Q1 2022[32] - Cash inflow from investment activities increased to 227,257,579.68 in Q1 2023, compared to 168,822,735.36 in Q1 2022[33] - Net cash flow from financing activities was -878,583,116.52 in Q1 2023, significantly worse than -10,680,989.20 in Q1 2022[33] - Total cash and cash equivalents at the end of Q1 2023 decreased to 193,769,345.45 from 547,167,168.51 in Q1 2022[33] - Cash received from operating activities related to other business activities was 375,155,082.27 in Q1 2023, down from 468,379,505.52 in Q1 2022[32] - Cash paid for employee compensation increased to 13,441,337.71 in Q1 2023 from 10,225,465.14 in Q1 2022[32] - Cash inflow from loans in Q1 2023 was 876,000,000.00, a decrease from 1,360,000,000.00 in Q1 2022[33] - Cash outflow for debt repayment rose to 1,712,367,200.00 in Q1 2023, compared to 873,798,400.26 in Q1 2022[33] - The net increase in cash and cash equivalents for Q1 2023 was -1,004,878,951.65, compared to -928,332,421.70 in Q1 2022[33] Assets and Liabilities - Total assets at the end of the reporting period were CNY 35,417,246,461.81, a decrease of 1.68% from the end of the previous year[5] - Total assets as of March 31, 2023, were RMB 35,417,246,461.81, down from RMB 36,023,021,753.09[14] - Total liabilities decreased to RMB 16,676,022,709.47 from RMB 18,080,738,769.39, a reduction of 7.8%[15] - Total current assets decreased to CNY 6,171,649,506.42 from CNY 6,995,556,470.48, a decline of approximately 11.8%[26] - Non-current assets totaled CNY 12,245,482,175.94, down from CNY 12,408,506,078.98, reflecting a decrease of about 1.3%[26] - Total assets amounted to CNY 18,417,131,682.36, a reduction of approximately 5.1% compared to CNY 19,404,062,549.46[26] - Total current liabilities decreased to CNY 6,290,470,518.98 from CNY 7,161,968,064.50, representing a decline of around 12.1%[26] Shareholder Equity - Shareholders' equity attributable to shareholders increased by 4.69% to CNY 15,742,386,028.25 compared to the end of the previous year[5] - Shareholders' equity increased to RMB 18,741,223,752.34 from RMB 17,942,282,983.70, an increase of 4.4%[15] Operational Costs and Expenses - Total operating costs for Q1 2023 were RMB 5,431,915,788.85, up 16.4% from RMB 4,664,211,013.43 in Q1 2022[17] - The company’s total operating expenses increased to ¥5,663,257,165.43, compared to ¥5,047,209,640.40 in Q1 2022[22] - Research and development expenses rose to ¥285,358,236.04, up 32.6% from ¥215,047,329.07 in Q1 2022[18] - Research and development expenses rose to CNY 2,989,495.66 from CNY 2,254,103.21, an increase of about 32.6%[29] Future Outlook - The increase in net profit after deducting non-recurring gains and losses was attributed to the recovery of hospital services and increased demand for related medications[6] - The company plans to continue expanding its market presence and investing in new product development[16]

证券代码：600079 证券简称：人福医药 公告编号：临 2023-037 号 人福医药集团股份公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2023 年 3 月 30 日（星期四）至 4 月 7 日（星期五）16:00 前登录上证路 演中心网站首页点击"提问预征集"栏目或通过公司邮箱 renfu.pr@renfu.com.cn 进行提问。 公司将在说明会上对投资者普遍关注的问题进行回答。 人福医药集团股份公司（以下简称"公司"）已于 2023 年 3 月 24 日发布公司《2022 年 年度报告》及《2022 年年度利润分配预案公告》，为便于广大投资者更全面深入地了解公 司 2022 年度经营成果、财务状况、利润分配方案等情况，公司计划于 2023 年 4 月 10 日下 午 15:00-16:30 举行 2022 年度业绩暨现金分红说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频结合网络文字互动召开，公 ...

Financial Performance - The company's operating revenue for 2022 was approximately ¥22.34 billion, representing an increase of 8.71% compared to ¥20.55 billion in 2021[17]. - Net profit attributable to shareholders reached approximately ¥2.48 billion, an increase of 88.60% from ¥1.32 billion in the previous year[17]. - The net profit after deducting non-recurring gains and losses was approximately ¥1.55 billion, up 53.92% from ¥1.01 billion in 2021[17]. - The weighted average return on equity increased to 17.63%, up 6.73 percentage points from 10.90% in 2021[18]. - Basic earnings per share rose to ¥1.54, an increase of 85.54% compared to ¥0.83 in 2021[18]. - The net cash flow from operating activities was approximately ¥2.44 billion, reflecting a 12.04% increase from ¥2.18 billion in 2021[17]. - Total assets at the end of 2022 were approximately ¥36.02 billion, a slight increase of 1.74% from ¥35.41 billion in 2021[17]. - The net assets attributable to shareholders increased by 16.13% to approximately ¥15.04 billion from ¥12.95 billion in 2021[17]. - The company reported a quarterly revenue of approximately ¥6.08 billion in Q4 2022, showing a consistent growth trend throughout the year[19]. Dividend and Shareholder Returns - The board of directors proposed a cash dividend of 1.60 RMB per 10 shares (including tax) to all shareholders, pending approval at the 2022 annual general meeting[4]. - The total cash dividend amount represents 10.52% of the net profit attributable to ordinary shareholders in the consolidated financial statements, which was 2,484,108,585.43 RMB[181]. Audit and Compliance - The company reported a standard unqualified audit opinion from Da Xin Certified Public Accountants[3]. - The company emphasizes the importance of the accuracy and completeness of the annual report, with all directors present at the board meeting[2]. - The company has complied with information disclosure regulations, ensuring timely, fair, and accurate reporting of significant events[147]. - The internal control audit report issued by Da Xin Accounting Firm confirmed that the company maintained effective internal controls over financial reporting in all material aspects[189]. Risk Management - The report includes detailed descriptions of potential risks faced by the company, as outlined in the management discussion and analysis section[5]. - The company is committed to enhancing risk management and cost reduction efforts while ensuring product quality[133]. - The company faces operational risks due to potential changes in tax policies affecting its subsidiaries, which currently enjoy tax incentives[137]. - The company is exposed to safety and environmental risks due to stricter regulations and increased oversight from safety and environmental authorities[140]. Research and Development - The company is focusing on R&D innovation, particularly in the fields of neurological drugs and steroid hormones, while also expanding its generic drug business in the U.S.[38]. - R&D expenses increased by 19.30% to approximately 966.86 million yuan, reflecting the company's commitment to innovation and development[51]. - The company has nearly 120 ANDA numbers, indicating a strong pipeline for generic drug development[38]. - The company has established R&D centers in Wuhan, Yichang, New Jersey, and St. Louis, employing 1,758 R&D personnel, including 196 PhDs and 7 experts receiving special government allowances[91]. - The company is actively involved in the research phase for various projects, indicating a commitment to innovation and market responsiveness[98]. Market Expansion and Strategy - The company actively explored international markets, with subsidiaries in Africa working on product registration despite local challenges[29]. - The company is focusing on expanding its market presence and clinical applications for ethnic medicine, particularly in Xinjiang[81]. - The company aims to enhance its marketing capabilities by building an academic promotion team and improving market access and clinical application[37]. - The company is strategically expanding its market presence through new product approvals and clinical trials, positioning itself for future growth[96]. Environmental Responsibility - The company has made significant investments in optimizing equipment and technological innovations to lower overall pollutant emissions[195]. - The company operates as a key pollutant discharge unit, with all subsidiaries' environmental facilities functioning normally[190]. - The company has established a mechanism for environmental protection and emphasizes the importance of pollution monitoring and waste disposal[190]. - The company is committed to green development and continuously improves its environmental management practices[190]. Corporate Governance - The company has a board of directors consisting of 9 members, including 3 independent directors, ensuring compliance with governance standards and protecting minority shareholders' interests[145]. - The company has established a performance evaluation system based on operational indicators and management objectives, with regular assessments of relevant governance personnel[146]. - The company has actively communicated with investors through various channels, including a dedicated investor hotline and online performance briefings[148]. - The company has strengthened internal control systems and revised financial management policies to prevent fund occupation by major shareholders[150]. Employee and Management Structure - The total number of employees in the parent company and major subsidiaries is 16,070, with 483 in the parent company and 15,587 in subsidiaries[173]. - The employee composition includes 3,762 production staff, 6,164 sales personnel, 3,295 technical staff, 359 financial staff, and 2,490 administrative staff[173]. - The company has established a comprehensive training and career development system, including various training programs to enhance employee skills and competencies[176]. - The company has implemented a performance-linked floating salary mechanism as part of its compensation policy to drive strategic planning and operational efficiency[175].